

Figure S1. Phenotypic characterization of imDCs and mDCs. Expression of the indicated antigens on imDCs (top) and mDCs (bottom) derived from a patient with oropharyngeal carcinoma. imDCs, immature dendritic cells; mDCs, mature dendritic cells; FITC, fluorescein isothiocyanate; PE, phycoerythrin; mAb, monoclonal antibody; HLA, human leukocyte antigen.




Figure S2. Negative control of the second stimulator for the assessment of WT1-specific CD4⁺ or CD8⁺ T cells. (A) Nonadherent cells were first stimulated with mDC/WT1 KP₃₇₋₄₅. The activated T cells were restimulated with imDCs alone as a control. (B) Dot plots of IFN- γ -producing CD4⁺ (top) and CD8⁺ T cells (bottom) derived from a patient with pancreatic ductal adenocarcinoma after stimulation with mDC/WT1 KP₃₇₋₄₅ and restimulation with imDCs alone. Representative plots of two independent experiments are presented. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; KP₃₇₋₄₅, killer peptide; mDC/WT1 KP₃₇₋₄₅, mDCs pulsed with WT1 KP₃₇₋₄₅; IFN- γ , interferon- γ .




Table SI. Percentage expression of indicated molecules in immature dendritic cells isolated from each patient.

Molecule	Patient 1	Patient 2	Patient 3	Patient 5	Patient 6	Patient 7	Patient 8	Patient 10	Patient 11	Patient 12	Patient 13	Patient 14	Mean expression
MHC class I	99.91	99.83	99.65	99.54	99.94	99.98	99.88	99.92	99.82	98.76	99.95	99.83	99.75±0.34
MHC class II	99.81	99.81	99.61	99.45	99.93	99.91	99.81	99.96	99.63	98.74	99.91	99.95	99.71±0.34
CD14	46.5	5.4	1.6	2.35	3.35	2.37	11.7	41.93	1.47	0.87	0.6	34.4	12.71±17.47
CD11c	99.7	99.2	99.49	98.74	99.94	99.87	99.4	99.9	98.97	99.37	99.8	99.9	99.52±0.4
CD80	20.71	11.22	18.13	4.6	23.67	25.99	36.65	16.23	12.2	2.2	11.43	17.59	16.72±9.47
CD86	89.1	96.9	95.7	93.34	98.6	95.2	91.1	95.6	96	98.36	95.3	95.4	95.05±2.74
CD40	98	94.9	91.2	71.2	99.1	97.9	97.7	98.6	91.4	87.1	98	98.1	93.6±8.01
CD83	15.62	45.25	35.2	18.5	34.28	36.11	26.82	21.12	56.69	31.9	33.82	18.93	31.19±11.98

Average values are presented as the mean ± SD. There were insufficient cells from patients 4 and 9 to analyze. MHC, major histocompatibility complex.

Table SII. Percentage expression of indicated molecules in mature DCs isolated from each patient.

Molecule	Patient 1	Patient 2	Patient 3	Patient 5	Patient 6	Patient 7	Patient 8	Patient 10	Patient 11	Patient 12	Patient 13	Patient 14	Mean expression	P-value
MHC class I	99.94	99.94	99.64	99.55	99.93	99.93	99.88	99.96	99.88	99.58	99.82	99.86	99.83±0.15	0.272
MHC class II	99.95	99.9	99.63	99.35	99.92	99.9	99.81	99.94	99.8	99.52	99.72	99.94	99.78±0.19	0.329
CD14	7.6	1.41	0.82	1.43	1.21	1.08	1.58	19.42	0.94	0.67	0.4	12.61	4.10±6.06	0.002
CD11c	99.4	98.6	98.82	98.53	99.81	99.88	98.84	99.7	98.92	98.66	99.4	99.7	99.19±0.51	<0.001
CD80	71.02	48.8	37.33	4.33	67.63	67.41	78.73	57.05	51.02	12.32	28.46	52.02	48.01±23.39	<0.001
CD86	99.1	99.8	99.2	95.29	99.9	99.8	99.6	99.1	99.8	99.1	98.7	99.3	99.06±1.25	0.002
CD40	99.3	98.76	94.1	69.6	99.5	99.31	98.77	99.7	98.96	90	97.9	99	95.41±8.62	0.021
CD83	80.62	94.28	80.8	54.01	94.33	97.74	95.65	72.33	94.67	72.9	79.8	72.08	82.43±13.35	<0.001

Average values are presented as the mean ± SD. P-value represents comparisons vs. immature DCs. There were insufficient cells from patients 4 and 9 to analyze. DC, dendritic cell; MHC, major histocompatibility complex.